Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Q2 EARNINGS: Lombard's first US quarter 'encouraging', Mindray slashes sales guidance

This article was originally published in Clinica

Executive Summary

Lombard Medical Technologies was “a bit light on results” during its first quarter as a US-listed company, noted Jefferies analyst Raj Denhoy. But more positively, “there were very encouraging signs for the commercial ramp of [its flagship product] Aorfix,” the analyst added. Aorfix is indicated for the endovascular treatment of abdominal aortic aneurysms (AAA). It got the go-ahead in the US in February 2013, and is currently the only product approved for use in patients with high-angle aneurysms of up to 90 degrees (who account for 30% of the EVAR market).

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT101832

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel